X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
E. Merck: The vitamin king consolidates - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

E. Merck: The vitamin king consolidates

Sep 30, 2000

E. Merck is the market leader in vitamins and derives over 60% of its turnover from this segment. Three of its vitamin brands Evion, Neurobion and Polybion contribute almost 45% of the company’s turnover. All three however are under price control and are likely to remain that way for some time to come. Over the last couple of years the company has made a mark in non–vitamin areas such as cardiology, topical anti–inflammatory and dermatologicals. During the last year it introduced Emadine and Emadine AT for controlling hypertension, Maxepa, a nutrition related cardiac drug, Cadvion for vascular metabolic function, Exflam gel an anti–inflammatory cream, Candistat capsules, a modern antibacterial, Harpoon tablets, a quinoline antibiotic, and Evion skin cream.

These products are likely to lead the company’s profitability in the future though the vitamin segment remains a major contributory factor to the turnover. E. Merck’s parent had also planned a tie–up with Seven Seas, which would have given the company another valuable OTC (over the counter) brand. However, this tie–up did not materialise.

Besides, E. Merck also has a non–pharma division comprising reagents, kits, pigments and paper rolls which accounts for almost 10% of its turnover. This has also witnessed new product introductions in the last two years. Manufacturing and marketing of vitamin/mineral premixes for food industry, addition of products for filtration, electronic balances, water purification systems, testing equipment for food and gas industry and substantial expansion of product range of laboratory reagents are some of the new introductions in the non-pharma division.

E Merck has been improving its financials, doubling its post tax profits in the first half of the current year. This was primarily due to an upward price revision in its vitamin brand Neurobion in June 2000. A part of the reason for this growth is that the company had written off VRS expenditure paid to the workers last year when it closed its chemical unit located at Taloja. (The write off of this had depressed the earnings last year.) Besides, the company also repaid a part of its borrowings last year and the reduction in interest cost has also contributed to the surge in the bottomline.

The stock quotes at Rs 349 which implies an earnings multiple of 16.6 times of FY01 estimates.


Equitymaster requests your view! Post a comment on "E. Merck: The vitamin king consolidates ". Click here!

  

More Views on News

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)

May 7, 2019

How a niche tech startup battled all odds to eventually become a 10 bagger.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


May 20, 2019 (Close)

TRACK MERCK

MERCK - TEVA PHARMA COMPARISON

COMPARE MERCK WITH

MARKET STATS